PT  - JOURNAL ARTICLE
AU  - Abdelouahed Alla hamou
AU  - Elhoussine Azroul
AU  - Zakia Hammouch
AU  - Abdelilah Lamrani alaoui
TI  - On dynamics of fractional incommensurate model of Covid-19 with nonlinear saturated incidence rate
AID  - 10.1101/2021.07.18.21260711
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.18.21260711
4099  - http://medrxiv.org/content/early/2021/07/23/2021.07.18.21260711.short
4100  - http://medrxiv.org/content/early/2021/07/23/2021.07.18.21260711.full
AB  - In December 2019, a new virus belonging to the coronavirus strain has been discovered in Wuhan, China, this virus has attracted world-wide attention and it spread rapidly in the world, reaching nearly 216 countries in the world in November 2020. In this chapter, we study the fractional incommensurate SIQR (susceptible, infections,quarantined and removed) COVID-19 model with nonlinear saturated incidence rate using Atangana–Baleanu fractional derivatives. The existence and uniqueness of the solutions for the fractional model is proved using fixed point theorem, the model are shown to have two equilibrium point (disease-free and an endemic equilibrium). Some numerical simulations using Euler method are also carried out to support our theoretical results. We estimated the value of the fractional orders and the parameters of the proposed model using the least squares method.. Further, the sensitivity analysis of the parameter is performed as a result, our incommensurate model gives a good approximation to real data of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNone